{"nctId":"NCT02267226","briefTitle":"Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery","startDateStruct":{"date":"2014-09"},"conditions":["Congenital Fibrinogen Deficiency"],"count":25,"armGroups":[{"label":"Octafibrin","type":"EXPERIMENTAL","interventionNames":["Drug: Octafibrin"]}],"interventions":[{"name":"Octafibrin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged ≥12 years (only 18 and above in Russia)\n* Documented diagnosis of congenital fibrinogen deficiency, expected to require on-demand treatment for bleeding or surgical prophylaxis:\n* Fibrinogen deficiency manifested as afibrinogenaemia or severe hypofibrinogenaemia.\n* Historical plasma fibrinogen activity of \\<50 mg/dL or levels below the limit of detection of the local assay method.\n* Expected to have an acute bleeding episode (spontaneous or after trauma) or planning to undergo elective surgery.\n* Informed consent signed by the subject or legal guardian.\n\nExclusion Criteria:\n\n* Life expectancy \\<6 months.\n* Bleeding disorder other than congenital fibrinogen deficiency, including dysfibrinogenaemia.\n* Prophylactic treatment with a fibrinogen concentrate.\n\nTreatment with:\n\n* Any fibrinogen concentrate or other fibrinogen-containing blood product within 2 weeks prior to start of treatment for the bleeding episode or surgery.\n* Any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs, warfarin, coumarin derivatives, platelet aggregation inhibitors) within 1 week prior to start of treatment for the bleeding episode or surgery, or as a planned or expected medication during the time period from Day 1 until 24 hours (i.e., 1 day) after the last Octafibrin infusion.\n\nPresence or history of:\n\n* Hypersensitivity to study medication.\n* Deep vein thrombosis or pulmonary embolism within 1 year prior to start of treatment for the bleeding episode or surgery.\n* Arterial thrombosis within 1 year prior to start of treatment for the bleeding episode or surgery\n* Hypersensitivity to human plasma proteins.\n* Oesophageal varicose bleeding.\n* End-stage liver disease (i.e., Child-Pugh score B or C).\n\nPregnant women within the first 20 weeks of gestation.\n\nCurrently breast-feeding.\n\nKnown positive HIV infection with a viral load \\>200 particles/μL or \\>400,000 copies/mL.\n\nPolytrauma 1 year prior to start of treatment for the bleeding episode or surgery.\n\nDiagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any time in the past.\n\nAcute or chronic medical condition which may, in the opinion of investigator, affect the conduct of the study, including\n\n* Subjects receiving immune-modulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to \\>10 mg/day), or similar drugs at study start.\n* Subjects having evidence or a history (within the previous 12 months) of abuse of any licit or illicit drug substance.\n\nParticipation in another interventional clinical study currently or during the past 4 weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient.","description":"The first bleeding episode covers the time period from the first Octafibrin infusion until 24 hours (i.e., 1 day) after the last infusion.\n\nThe investigator's overall clinical assessment of haemostatic efficacy for bleeding was based on a 4 point haemostatic efficacy scale. The final efficacy assessment of each patient was adjudicated by the Independent Data Monitoring \\& Endpoint Adjudication Committee (IDMEAC).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Clot Firmness (MCF) After Fibrinogen Infusion in Each Documented Bleeding Episode (BE), Measured in Frozen Plasma in a Central Laboratory.","description":"MCF (mm) was determined using ROTEM and was used as a surrogate marker for haemostatic efficacy. ROTEM is a method for the continuous measurement of clot formation and clot firmness. It utilises a mechanical detection system which is based on the ability of the blood or plasma clot to form a mechanical coupling over a distance of 1 mm.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":"2.53"}]}]}]},{"type":"SECONDARY","title":"Fibrinogen Plasma Level","description":"Fibrinogen plasma level was assessed using the Clauss fibrinogen assay","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"1.17"},{"groupId":"OG001","value":"109.01","spread":"24.38"},{"groupId":"OG002","value":"104.46","spread":"21.51"},{"groupId":"OG003","value":"70.77","spread":"20.59"}]}]}]},{"type":"SECONDARY","title":"Response as Indicated by Incremental in Vivo Recovery (IVR)","description":"Incremental IVR (response): calculated as the maximum increase in plasma fibrinogen (i.e., Clauss data) between pre-infusion and 1 and 3 hours post-infusion, divided by the exact dose of Octafibrin.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Efficacy of Octafibrin for All Bleeding Episodes Collected in the Study","description":"The investigator's overall clinical assessment of haemostatic efficacy for bleeding will be based on a 4-point haemostatic efficacy scale. The final efficacy assessment of each patient will be adjudicated by the Independent Data Monitoring \\& Endpoint Adjudication Committee (IDMEAC)","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Octafibrin in Preventing Bleeding During and After Surgery","description":"The efficacy of Octafibrin will be assessed at the end of surgery by the surgeon and post-operatively by the haematologist using two 4-point haemostatic efficacy scales. An overall efficacy assessment taking both the intra- and post-operative assessment into account will be adjudicated by the IDMEAC","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Analysis of Safety: Immunogenicity Testing for Anti-fibrinogen Antibodies","description":"Immunogenicity testing for the presence of anti-fibrinogen antibodies at Day 14 and Day 30 after the administration of Octafibrin for bleeding. An experimental non-standard ELISA was developed for this study for evaluating anti-fibrinogen antibodies. No specific test was performed to discern for neutralizing antibodies. The clinical implications of the assay results are not known.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":25},"commonTop":["Limb injury","Pain in extremity","Gingival bleeding","Vomiting","Hypertension"]}}}